Literature DB >> 15208685

Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia.

Ignacio Flores1, Daniel J Murphy, Lamorna Brown Swigart, Ulrike Knies, Gerard I Evan.   

Abstract

The homeostatic integrity of skin epidermis is maintained by a balance between keratinocyte proliferation, on one hand, and terminal differentiation combined with outward migration and shedding, on the other. Perturbation of this balance in favor of proliferation can result in hyperplasia and, potentially, tumorigenesis. We have previously described a reversible transgenic mouse model of epidermal neoplasia in which expression of an acutely regulatable form of Myc, MycERTAM, is targeted to epidermis via the involucrin promoter. In this model, sustained activation of MycERTAM induces a complex neoplastic lesion involving marked hyperplasia of less-differentiated suprabasal cells, angiogenesis and overt papillomatosis. Subsequent deactivation of MycERTAM triggers complete papilloma regression. Here, we provide evidence that Myc-induced papillomas are self-limiting because of the eventual differentiation of MycERTAM-expressing keratinocytes. Thus, keratinocyte differentiation eventually prevails over Myc-induced proliferation. We also show that regression of Myc-induced papillomas following MycERTAM deactivation occurs through a combination of growth arrest and irreversible differentiation. Finally, we demonstrate that transient deactivation of Myc is sufficient to expel keratinocytes irreversibly from the proliferative compartment and render them refractory to the mitogenic influence of subsequent Myc reactivation. Such observations illustrate the potential utility of even short-term inhibition of oncogenic lesions in the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15208685     DOI: 10.1038/sj.onc.1207796

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  28 in total

1.  MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms.

Authors:  Dean W Felsher
Journal:  Genes Cancer       Date:  2010-06

Review 2.  Mitotic and mitogenic Wnt signalling.

Authors:  Christof Niehrs; Sergio P Acebron
Journal:  EMBO J       Date:  2012-05-22       Impact factor: 11.598

3.  Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia.

Authors:  Zhifu Xiang; Hui Luo; Jacqueline E Payton; Jennifer Cain; Timothy J Ley; Joseph T Opferman; Michael H Tomasson
Journal:  J Clin Invest       Date:  2010-05-17       Impact factor: 14.808

Review 4.  Therapeutic strategies to inhibit MYC.

Authors:  Michael R McKeown; James E Bradner
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-01       Impact factor: 6.915

5.  An "-omycs" Toolbox to Work with MYC.

Authors:  Jonathan Whitfield; Laura Soucek
Journal:  Methods Mol Biol       Date:  2021

6.  Transcriptional amplification in tumor cells with elevated c-Myc.

Authors:  Charles Y Lin; Jakob Lovén; Peter B Rahl; Ronald M Paranal; Christopher B Burge; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2012-09-28       Impact factor: 41.582

7.  Genetic analysis of myc and telomerase interactions in vivo.

Authors:  Ignacio Flores; Gerard Evan; María A Blasco
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

8.  Inauhzin(c) inactivates c-Myc independently of p53.

Authors:  Ji Hoon Jung; Jun-Ming Liao; Qi Zhang; Shelya Zeng; Daniel Nguyen; Qian Hao; Xiang Zhou; Bo Cao; Sung-Hoon Kim; Hua Lu
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

9.  MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma.

Authors:  Adlai R Grayson; Erica M Walsh; Michael J Cameron; Jernej Godec; Todd Ashworth; Jessica M Ambrose; Alexandra B Aserlind; Hongfang Wang; Gerard Evan; Michael J Kluk; James E Bradner; Jon C Aster; Christopher A French
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

10.  Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation.

Authors:  Deborah J Marble; Kenneth B Gordon; Brian J Nickoloff
Journal:  J Dermatol Sci       Date:  2007-08-08       Impact factor: 4.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.